WuXi XDC and Celltrion Partner to Offer Extensive Antibody-Drug Conjugate (ADC) Services

Published February. 22. 2024

WuXi XDC (2268.HK), a prominent Contract Research, Development, and Manufacturing Organization (CRDMO) globally recognized for its focus on the ADC and other bioconjugate markets, has joined forces with Celltrion, Inc. (068270.KS), a leading biopharmaceutical company dedicated to researching, developing, and manufacturing innovative therapeutics for global well-being. The two entities have formalized their collaboration through the signing of a Memorandum of Understanding (MOU), outlining their commitment to providing comprehensive and integrated services for the development and manufacturing of bioconjugates, including antibody-drug conjugates (ADCs).

In this partnership, Celltrion designates WuXi XDC as its primary service provider for integrated projects across the globe, entrusting responsibilities from process development to GMP manufacturing. WuXi XDC assumes the role of a strategic service partner, actively supporting Celltrion’s advancements in its innovative pipeline. The collaboration aims to expedite ADC development with a focus on speed and high-quality outcomes.

Jong Moon Cho, VP of Celltrion, emphasized the importance of innovation in addressing unmet needs and contributing to healthcare system sustainability. He expressed confidence in WuXi XDC as an ideal partner due to its advanced platform and extensive expertise in ADC development and manufacturing. Cho sees the collaboration as an exciting opportunity to accelerate pipeline development, ultimately benefiting patients on a global scale.

Dr. Jimmy Li, CEO of WuXi XDC, expressed satisfaction in partnering with Celltrion to fast-track their innovative pipeline. With a fully integrated, one-stop platform, WuXi XDC is poised to collaborate closely with Celltrion to hasten the development and manufacturing processes for ADCs and other bioconjugate candidates. As a global CRDMO, WuXi XDC remains steadfast in its commitment to facilitating clients’ endeavours in advancing innovative therapeutics swiftly and with uncompromised quality, contributing to the goal of benefiting patients worldwide in the years to come.


About Wuxi XDC

WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK) is a leading global CRDMO focused on antibody-drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.



Get the free newsletter

Subscribe to IMAPAC for top news, trends & analysis

Download Brochure Sample

    Subscribe To Our Mailing List
    By checking the box, you acknowlege and agree to IMAPAC's Term of Service and to use your contact information provided to communicate with about offerings by IMAPAC, its brands, affliates and/or third-party partners consistent with IMAPAC's Privacy Policy..